Calciumgluconat B.Braun 10% is an intravenous solution applied in addressing symptoms related to acute symptomatic hypocalcemia (abnormally low blood calcium levels). This condition is characterized by a temporary physiological imbalance due to acute electrolyte disturbances. This medicine is considered relevant in contexts involving heightened systemic burden.

The medication helps address symptoms that interfere with daily functioning and are related to symptoms of increased neurological or muscular activity. These symptoms may include tetany, muscle cramps, and tingling sensations. The primary therapeutic areas where this medicine is used involve acute hypocalcemia, conditions associated with acute or disruptive episodes due to severe hyperkalaemia, and magnesium overdose. This intervention provides supportive relief when symptoms become temporarily overwhelming, contributing to improved comfort during symptomatic periods. It is applied in scenarios where additional management of discomfort is required.

In clinical settings that involve acute or unstable symptom patterns, calcium gluconate is also a relevant intervention. It is applied across domains where additional symptomatic support is needed, such as in conditions presenting with systemic or localized discomfort due to elevated blood potassium (severe hyperkalaemia) and magnesium overdose (hypermagnesemia). This use assists with maintaining functional stability during episodes of heightened physiological activity and systemic burden.

Quick Fact: Relief for Symptoms related to increased neurological or muscular activity

Regulatory References

1. NIH DailyMed official labeling

Who Can and Cannot Use Calciumgluconat B.Braun 10%?

This eligibility profile is defined by official regulatory documents and establishes groups who are approved for use, those who require caution, and those who must not use the medicine.

Contraindications (Must Not Use)

Classification	Population/Condition
Metabolic	Patients with high calcium levels (Hypercalcaemia or Hypercalciuria).
Cardiac	Patients receiving Cardiac Glycoside Therapy (e.g., Digitalis).
Pediatric	Neonates (under 28 days) receiving concomitant Ceftriaxone.

Use with Restriction or Caution

Adults and Pediatric Patients are generally eligible for intravenous use, but the intramuscular (IM) route is prohibited in all children and adolescents.

Restriction Focus	Population/Condition
Organ Function	Use in patients with Impaired Renal Function requires caution; prolonged or repeated treatment is prohibited due to aluminum accumulation risk.
Life Stage	Pregnant women should not use the medicine unless it is indispensable. Breast-feeding requires a decision to discontinue nursing or therapy.
Comorbidity	Use requires caution in the Elderly and in patients with certain conditions like Sarcoidosis or pre-existing Heart Diseases.

Interactions with other medicines and products

The interaction profile for intravenous Calcium Gluconate 10% centers on two main official regulatory constraints: absolute prohibition and modification of systemic calcium exposure.

---

Contraindicated Combinations and Administration Restrictions

Classification Type	Official Regulatory Statement
Absolute Contraindication	Intravenous administration is prohibited in patients receiving Cardiac Glycosides (e.g., Digoxin) due to the documented risk of synergistic cardiac arrhythmias.
Neonatal Contraindication	Co-administration of Ceftriaxone is absolutely forbidden in neonates (le 28 days of age) due to the risk of fatal precipitation.
Simultaneous Prohibition	Simultaneous infusion of Ceftriaxone and calcium-containing solutions via a Y-site is prohibited in all age groups.

---

Documented Pharmacodynamic and Exposure Interactions

Interaction Type	Interacting Substance/Class	Official Interaction Statement
Exposure Modification	Thiazide Diuretics	Co-administration may cause hypercalcaemia by decreasing the renal excretion of calcium.
Pharmacodynamic Antagonism	Calcium Channel Blockers	Administration of calcium may reduce the therapeutic effect of these agents.
Additive Effect	Vitamin D Analogs	Increases the risk of hypercalcaemia due to additive effects.

---

Timing and Physical Incompatibility

Sequential administration of Ceftriaxone and calcium in non-neonates is subject to the condition that the intravenous lines are thoroughly flushed with a compatible fluid between infusions. Furthermore, the solution is chemically incompatible with fluids containing Phosphate or Bicarbonate, which results in precipitation if mixed.

How Calciumgluconat B.Braun 10% Works

Calcium Gluconate's mechanism is defined by direct electrolyte repletion, rapidly increasing the concentration of the Ca^2+ ion in the plasma to influence three critical biological domains.

---

Membrane Stabilization and Neuromuscular Control

The core action involves Ca^2+ binding to the plasma membrane of excitable cells, functioning as a membrane potential modulator. This interaction alters the cell's electrical threshold, primarily by influencing voltage-gated Na^+ channels. This mechanism modifies the excitability of nerve cells and motor neurons, which results in the physiological outcome of modulating neuromuscular excitability.

---

Excitation-Contraction Coupling and Cofactor Activity

By raising the extracellular Ca^2+ concentration, the drug enhances the influx of calcium through L-type channels into cardiac and smooth muscle cells, directly supporting the excitation-contraction coupling cascade. The surge in available Ca^2+ binds to the contractile protein Troponin C, initiating mechanical force generation. Concurrently, the Ca^2+ ion serves as an indispensable cofactor (Factor IV) required for the activation of multiple enzymes in the blood coagulation cascade. Separately, it exerts functional antagonism against the membrane-destabilizing effects of excess potassium ( K^+) on the heart, functionally modulating cardiac excitability.

Calciumgluconat B.Braun 10% is administered exclusively via the intravenous (IV) route as either a slow injection (bolus) or a continuous infusion, strictly in a monitored clinical setting. The injection must not be given intramuscularly or subcutaneously.

Dosing and Preparation

The dosage regimen is determined by the patient's age and condition, and the solution is intended for acute, short-term use only.

• Adult Dosing: The standard initial bolus dose is 1000 mg to 2000 mg (10 mL to 20 mL of the 10% solution). This dose may be repeated every 6 hours as required, or followed by a continuous infusion. For hyperkalemia, a dose of 15 mL to 30 mL is used for cardiac membrane stabilization.
• Pediatric Dosing: Doses for neonates and children are calculated based on body weight (mg/kg) and differ significantly from adult regimens.
• Dilution: For bolus administration, the 10% solution must be diluted in 5% dextrose or normal saline to a concentration of 10 mg/mL to 50 mg/mL before use. Continuous infusion requires dilution to 5.8 mg/mL to 10 mg/mL.

Administration Constraints

Strict rate limits are required to control administration. The maximum rate of IV bolus infusion is 200 mg/minute for adults and 100 mg/minute for all pediatric patients. During administration, continuous monitoring of patient vitals and an Electrocardiograph (ECG) is a required procedural element. Dosage is adjusted based on measured serum calcium levels, particularly in populations like those with renal impairment.

Evidence for Use in Acute Symptomatic Hypocalcemia

Studies, including Randomized Controlled Trials (RCTs), have investigated intravenous calcium salts for acute symptomatic hypocalcemia. Researchers primarily examined outcomes related to systemic imbalance, such as ionized and total calcium levels and the resolution of severe clinical signs like tetany and seizures. Studies reported measurements showing an increase in serum calcium concentration. The research is used by regulators to address the use of intravenous calcium in acute calcium repletion. This research generally focuses on the immediate, acute correction phase, meaning long-term effects are not fully established.

---

Evidence for Use in Severe Hyperkalaemia (Elevated Blood Potassium)

For conditions involving elevated blood potassium, research relies on observational studies and physiological principles to examine the effect on heart function. Study outcomes examined focused on physiological strain, specifically tracking ECG changes (like the reversal of abnormalities). Studies described observations that the administration was associated with a change in myocardial membrane stability. This is described as a temporary physiological effect. The medicine does not address the underlying cause of the high potassium levels, and certainty surrounding its long-term application remains low.

---

Evidence for Use in Hypermagnesemia (Magnesium Overdose)

Research into the use of calcium gluconate as an antidote for acute magnesium overdose relies mainly on Case Reports and Clinical Reviews. Research examined the primary outcomes related to systemic imbalance, including the loss and recovery of deep tendon reflexes and the restoration of normal function. Studies reported that calcium was observed in some studies to act as a physiological antagonist to magnesium. Evidence quality varies across studies, and the sample sizes were modest.

---

Evidence Gaps and Special Populations

Research has examined pediatric patients including critically ill infants and neonates for acute hypocalcemia. However, follow-up durations were limited across all indications, meaning long-term effects are not fully established. Furthermore, comparative evidence is lacking in some contexts, and data for certain groups remain insufficient.

Key Studies & References

1. Calcium Gluconate Injection official DailyMed Labeling
2. World Health Organization (WHO) Model List of Essential Medicines
3. NIH/NCBI Review on Calcium Metabolism and Disorders

Common questions about Calciumgluconat B.Braun 10% (FAQ)

---

Q: Can this injection be used for problems other than just low calcium?

Official documents describe its use for medical conditions beyond just low calcium levels. This medication is also described as being used to prevent abnormal heart rhythms resulting from severe high potassium levels (hyperkalemia) or to counteract the effects of an acute magnesium overdose (hypermagnesemia).

---

Q: Why does the packaging mention a component called 'calcium-D-saccharat-Tetrahydrate'?

This component, known as calcium saccharate, is included in the solution as a stabilizing agent. Its purpose is to help maintain the stability and solubility of the main active ingredient, calcium gluconate, within the liquid solution.

---

Q: What is the difference between calcium gluconate and calcium chloride?

Regulatory documents indicate that these two solutions are not interchangeable. This is because 10 mL of the 10% calcium gluconate solution contains significantly less elemental calcium (the active calcium ion) than the same volume of 10% calcium chloride solution.

---

Q: What is the elemental calcium content in this 10% solution?

According to official prescribing information, each 10 mL of the 10% calcium gluconate solution contains approximately 93 to 94 mg of elemental calcium ( Ca^2+). This value represents the amount of active calcium available to the body.

---

Q: Does the drug have to be diluted before it is administered?

Official instructions indicate that the concentrated solution requires dilution before administration. It is typically mixed with compatible intravenous fluids like 5% dextrose or normal saline prior to being given to the patient.

---

Q: What should the liquid look like before it is injected—is a cloudy solution acceptable?

The solution must be visually inspected before use. Official guidance states it should be clear, colorless to light brown, and practically free from any visible particles. A cloudy solution or one containing solid particles should not be used.

---

Q: How quickly does the effect of the calcium injection start working?

For acute uses, such as stabilizing the heart in severe high potassium, official sources describe the effects on heart function (ECG changes) as occurring within a few minutes.

---

Q: How long does the effect of the injection typically last?

The effect of the medicine for acute stabilization, such as addressing severe high potassium, is described as temporary, lasting around 30 to 60 minutes. This temporary effect is why continuous monitoring may be necessary.

---

Q: Why is continuous monitoring of serum calcium levels necessary during and after treatment?

The monitoring of serum calcium levels is a regulatory requirement that allows healthcare providers to adjust the dosage as needed. This process helps ensure that calcium levels are stabilized and aids in avoiding potential complications related to both calcium deficiency and high calcium excess.

---

Q: Is it normal to feel a flushing or warming sensation when the injection is being given?

Regulatory documents note that sensations of heat, tingling, or hot flushes can occur following the intravenous administration of calcium gluconate.

---

Q: What happens if the injection is given too fast?

Rapid intravenous administration is associated with severe reactions like a sudden drop in blood pressure, a slow heart rate, and irregular heart rhythms, which is associated with the risk of severe complications, including cardiac arrest.

---

Q: Can this drug cause high blood pressure or low blood pressure?

A sudden drop in blood pressure (hypotension) is specifically associated with the injection being administered too rapidly. Additionally, official information indicates that high blood pressure (hypertension) can be a reported symptom if blood calcium levels become too high (hypercalcaemia).

---

Q: What does 'extravasation' mean in relation to this medication?

Extravasation refers to the unintentional leakage of the medicine from the vein into the surrounding soft tissue during injection. This is a significant safety concern because the injection is highly irritant.

---

Q: What is the risk of tissue damage at the injection site?

The injection is described as highly irritant. If extravasation occurs, it carries a serious risk of local soft tissue inflammation, potential tissue death (necrosis), and the formation of calcium deposits in the skin (calcinosis cutis).

---

Q: What are the signs of having too much calcium in the blood (hypercalcaemia) after the injection?

Symptoms of abnormally high blood calcium levels (hypercalcaemia) listed in official documents include loss of appetite, feeling sick, vomiting, and constipation. Other signs may involve increased thirst, excessive urination, muscle weakness, or confusion.

---

Q: Can a patient with a history of sarcoidosis receive this injection?

Official warnings advise that using this medicine in patients with sarcoidosis (an inflammatory disease) requires careful consideration. It is indicated that the medicine should only be administered if it is absolutely essential.

---

Q: Is there a possibility that the injection could weaken the effects of adrenaline (epinephrine)?

Official prescribing information notes that administering calcium together with adrenaline (epinephrine) after heart surgery is described as weakening adrenaline's effects on the heart and circulation.

---

Q: What types of IV fluids cannot be mixed with the drug?

The solution is known to be chemically incompatible with IV fluids that contain either phosphate or bicarbonate. Mixing with these substances results in precipitation (the formation of solid particles).

---

Q: Is there a risk of aluminum exposure from using this product, especially with long-term treatment?

Official labeling confirms the product contains trace amounts of aluminum. There is a documented risk of aluminum toxicity with prolonged use, particularly for patients with impaired kidney function.

---

Q: Is it safe to breastfeed after being given this injection?

Official information states that it is not known if the drug is excreted into human milk. The official product information indicates that a decision must be made regarding either temporarily discontinuing breastfeeding or discontinuing the therapy.

---

Q: Are there research studies supporting the use of this specific B. Braun brand of calcium gluconate?

This specific B. Braun product has been granted a marketing authorization by regulatory agencies. This approval confirms that data supporting its quality, safety, and intended use were formally assessed and accepted.

---

Q: Does this injection interact with blood pressure medications like calcium channel blockers or beta-blockers?

Official warnings indicate that calcium may reduce the therapeutic effect of certain blood pressure regulators known as calcium antagonists. An interaction with certain oral beta-blockers has also been described.

---

Q: Is it possible to be allergic to Calciumgluconat B.Braun 10%?

As with any medicine, an allergic reaction is possible. Official information on adverse effects states that signs may include difficulty breathing, swelling, or rash, and prompt medical attention would be required if they occur.

How to Store and Dispose of Calciumgluconat B.Braun 10%

Official Storage Requirements

This medication must be stored at a controlled room temperature between 15 C and 30 C (59 F and 86 F). The unopened solution should be protected from light until the time of use. The solution should be inspected for particles; if a precipitate is present, instructions exist for resolving it by warming the vial and then cooling to room temperature. The product must be kept out of the sight and reach of children.

Handling and Disposal

The injection is designated for single use only, and any unused portion remaining in the container after administration must be discarded immediately. If a Pharmacy Bulk Package is used, dispensing of single doses must be completed within four hours of first penetrating the closure. Disposal of unused product or waste material must be carried out according to local requirements.